AstraZeneca struck a potentially multibillion-dollar obesity and diabetes collaboration with China’s CSPC Pharmaceuticals, paying $1.2B upfront with total deal value possibly exceeding recent blockbusters, making it the largest obesity deal to date according to DealForma. Read it here
